ABOUT

The 2025 Nobel Prize in Physiology or Medicine, awarded to Drs. Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their discoveries concerning peripheral immune tolerance, marks a transformative milestone in immunology. Their pioneering work laid the foundation for understanding immune tolerance.

The 2024 Nobel Prize in Physiology or Medicine, awarded to Drs. Victor Ambros and Gary Ruvkun for their discovery of microRNA (miRNA) and its role in gene regulation, opened new frontiers in understanding gene regulation and disease mechanisms — positioning miRNA-based therapies at the forefront of medical innovation.

Dr. Xiangfei "Scott" Cheng is the sole inventor of hundreds of U.S. patent–filed innovations. His earlier U.S. patent–filed innovations resonate with the foundational principles later recognized by the 2024 and 2025 Nobel Prizes in Physiology or Medicine, pioneering the frontiers of targeted immune regulation and precise gene regulation. Among these novel molecules are some that specifically regulate the Nobel Prize–recognized pathways, creating new therapeutic opportunities in autoimmune diseases, cancers, and organ transplantation, as well as others that modulate gene expression to target cancers, autoimmune and inflammatory diseases, traumatic brain injury (TBI), neurodegenerative disorders, immunomodulation, and lung fibrosis. 

His innovations span miRNA-based therapies, immunomodulation, immunotherapies, CAR-T combination treatments, small molecules, and cell and gene therapies, as well as biomarker discovery assays, diagnostics, precision medicine, and AI-driven platforms for translational medicine, clinical development, and assistive devices for individuals with disabilities.

To save patients' lives, he founded Allphild Inc to advance these innovative molecules into life-saving drugs.  Additionally, the company is dedicated to develop immunotherapy, cell and gene therapies, and small-molecule therapies for cancers and other diseases. 

Allphild Inc stands at the forefront of biopharmaceutical innovation, committed to transforming lives through cutting-edge research and development. Specializing in novel drug therapies for traumatic brain injury (TBI), cancers, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases, organ transplantation, and vaccine development, we are driven by our mission to save lives.

Our commitment to innovation drives us to explore novel therapeutic solutions for the most challenging medical conditions. With a passionate team of world-class scientists and researchers, we tirelessly pursue breakthroughs that redefine therapy across multidisciplinary fields. Leveraging the latest advancements in biotechnology, we strive to push the boundaries of what’s possible in healthcare. Explore our website to learn more about our groundbreaking research and development.